Pfizer forecasts revenue from the COVID-19 vaccine it developed with BioNTech will now attain $36 billion this year, up 7.5% from its outdated estimate of $33.5 billion.
Why it concerns: This vaccine has instantly become the highest-promoting drug on earth, but public health experts and international leaders remain concerned concerning the vaccine's uneven distribution which has left poorer international locations with a ways fewer doses to administer.
dwell on true of the latest market trends and financial insights with Axios Markets. Subscribe for free of charge
by using the numbers: Pfizer registered $13 billion of actual COVID-19 revenue within the third quarter, bringing 12 months-to-date 2021 sales to $24.3 billion.
Pfizer mentioned its profit margin on the vaccine, earlier than taxes and after splitting earnings with BioNTech, is the "excessive 20s," which means vaccine profits might strategy $10 billion only for Pfizer thi s year.
Pfizer expects the vaccine will generate an further $29 billion of earnings in 2022, and that's the reason based simplest on 1.7 billion doses dedicated to buying contracts.
Pfizer talked about it's going to manufacture up to four billion doses next yr, which means there are 2.3 billion doses it could nevertheless promote.
The final analysis: The Pfizer-BioNTech vaccine is extraordinarily helpful and has saved millions of lives. it be additionally develop into of the greatest moneymakers in pharmaceutical heritage.
more from Axios: sign in to get the newest market developments with Axios Markets. Subscribe without charge
0 Comments